Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer
Authors
Keywords
Cancer treatment, Ovarian cancer, Mouse models, Nanoparticles, Cerium, Endothelial cells, Growth factors, Angiogenesis
Journal
PLoS One
Volume 8, Issue 1, Pages e54578
Publisher
Public Library of Science (PLoS)
Online
2013-02-01
DOI
10.1371/journal.pone.0054578
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo
- (2015) Ramandeep Rattan et al. NEOPLASIA
- Combined cytotoxic and anti-invasive properties of redox-active nanoparticles in tumor–stroma interactions
- (2011) Lirija Alili et al. BIOMATERIALS
- Overview of anti-angiogenic agents in development for ovarian cancer
- (2011) Robert A. Burger GYNECOLOGIC ONCOLOGY
- The protective effects of cerium oxide nanoparticles against hepatic oxidative damage induced by monocrotaline
- (2011) Kamal Amin et al. International Journal of Nanomedicine
- From Nanotechnology to Nanomedicine: Applications to Cancer Research
- (2010) R. Seigneuric et al. CURRENT MOLECULAR MEDICINE
- Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival
- (2010) Felicity Lose et al. GYNECOLOGIC ONCOLOGY
- Bevacizumab toxicities and their management in ovarian cancer
- (2010) Leslie M. Randall et al. GYNECOLOGIC ONCOLOGY
- Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab
- (2010) Nisha Bansal et al. GYNECOLOGIC ONCOLOGY
- Emerging nanomedicines for early cancer detection and improved treatment: Current perspective and future promise
- (2010) Dhruba J. Bharali et al. PHARMACOLOGY & THERAPEUTICS
- Brain Distribution and Toxicological Evaluation of a Systemically Delivered Engineered Nanoscale Ceria
- (2010) Sarita S. Hardas et al. TOXICOLOGICAL SCIENCES
- Angiogenesis and ovarian cancer
- (2009) César Gómez-Raposo et al. Clinical & Translational Oncology
- Antiangiogenic drugs in ovarian cancer
- (2009) Maurie Markman EXPERT OPINION ON PHARMACOTHERAPY
- Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner
- (2009) R. Rattan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors
- (2009) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- PEGylated Nanoceria as Radical Scavenger with Tunable Redox Chemistry
- (2009) Ajay S. Karakoti et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
- (2008) Masuko Ushio-Fukai et al. CANCER LETTERS
- Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells
- (2008) David W. Chan et al. CARCINOGENESIS
- Nanoceria as antioxidant: Synthesis and biomedical applications
- (2008) A. S. Karakoti et al. JOM
- The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe Disease
- (2008) Shailendra Giri et al. JOURNAL OF NEUROCHEMISTRY
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started